Sponsored By
PlasticsToday Staff

September 5, 2016

2 Min Read
Nestle Health Science agrees to conditional purchase of Phagenesis

Nestlé Health Science (NHSc; Epalinges, Switzerland) announced on Sept. 1 that it has entered into a staged, milestone-based acquisition of medical device company Phagenesis. The company, which is headquartered in Manchester, UK, has developed a new treatment for dysphagia, the inability to swallow safely.

Under the terms of the agreement, NHSc will make an upfront payment, followed by milestone-based funding, while Phagenesis completes the clinical evaluation of its Phagenyx device, according to a news release. The staged acquisition will be based upon successful completion of European and U.S. development programs anticipated by 2019. Financial terms were not disclosed.

Dysphagia occurs in around 29% to 55% of stroke patients, with 15 million people worldwide suffering a stroke every year, according to data cited by Nestlé in the release. It is also a common consequence of numerous other diseases, and is often under-diagnosed in various patient populations.

Current available options can improve the status and symptoms of dysphagia, but few treat the cause. Phagenesis has developed Phagenyx, a medical device designed to restore the neurological control of swallowing. Phagenyx is based on groundbreaking research that establishes a mechanism of action of delivering Pharyngeal Electrical Stimulation to treat the neurological cause of dysphagia. In essence, it restores neurological control of swallowing by kick-starting the re-organization of the brain, explains Phagenesis.

Gunnar Weikert, Director of Phagenesis and founder of Inventages Venture Capital, commented: "As a long-term investor in Phagenesis, we are pleased about this significant investment by Nestlé Health Science."

Greg Behar, CEO of Nestlé Health Science, stated: "Dysphagia is a strategic focus for Nestlé Health Science. This innovation can bring a new dimension to swallowing rehabilitation that can be transformational from a patient and healthcare professional perspective."

A wholly owned subsidiary of food and beverage giant Nestlé, NHSc is focused on advancing nutritional therapy technology and employs approximately 3,000 people worldwide.

Sign up for the PlasticsToday NewsFeed newsletter.

You May Also Like